Kopin - Q3 2024

Executive Summary

• Q3 revenue rose 26% year over year to $13.3M, with defense product sales up 109% to $10.4M; product gross cost ratio improved to 76% of product revenue (implying ~24% product gross margin) vs 99% a year ago, driven by favorable mix and quality gains. Net loss was ($3.5)M or ($0.03) per share vs ($2.5)M ($0.02) last year.
• Management highlighted record order momentum, projecting over $75M of 2024 orders (potentially the highest in company history), though Q3 book-to-bill was slightly below 1:1; quality acceptance at top customers reached 94% in Q3/October, and gross margin improvement is planned to continue into Q4.
• Strategic milestones include final production validation of the next‑gen OLEDoS display for the F‑35 HMDS and a $2M follow‑on AMLCD order to support current F‑35 production, positioning Kopin as the sole display supplier across two generations.
• Estimates context: S&P Global consensus data was unavailable at the time of analysis (system limit). One analyst on the call noted revenue was “a bit better than we had expected,” but no quantification was provided.

What Went Well and What Went Wrong

• What Went Well

  • Defense strength and mix: Defense product revenue more than doubled (+109% y/y) to $10.4M; product cost ratio fell to 76% (vs 99%), reflecting favorable mix and improved quality.
  • Program milestones and orders: Completed final production validation of OLEDoS for F‑35 HMDS and received a $2M follow‑on AMLCD order; also secured a $1.3M follow‑on Emerald module order for a major weapon sight.
  • Execution and quality: Incoming inspection acceptance at top customers reached 94% in Q3 and October (up from 86% in the prior quarter), supporting margin expansion; management plans continued margin improvement into Q4.
  • Quote: “We now project over $75 million in orders for 2024 and beyond, potentially the highest annual order total in our Company's 40-year history.” — Michael Murray, CEO.

• What Went Wrong

  • R&D revenue decline: Funded R&D revenue fell 54% y/y to $2.3M as programs were completed and moved to low‑rate initial production.
  • Operating loss and legal overhang: Net loss widened y/y to ($3.5)M on higher SG&A (legal), including a $1.1M non‑cash impairment; broader year-to-date results include litigation-related accruals earlier in 2024, leaving a legal overhang pending appeals.
  • Book-to-bill in Q3: Q3 book-to-bill was slightly below 1:1, though YTD remains ahead of schedule; international revenue still <5% of FY24 but expected to grow with incremental investment.

Transcript

Operator (participant)

Good morning, everyone, and welcome to the Kopin Corporation Third Quarter 2024 earnings call. Please note that this event is being recorded. At this time, I would like to turn the conference over to Brian Prenoveau, Investor Relations for Kopin. Please go ahead.

Brian Prenoveau (Head of Investor Relations)

Thank you, Operator, and good morning, everyone. Before we get started, I'd like to remind everyone that during today's call, taking place on Tuesday, November 12th, 2024, we will be making forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations, projections, beliefs, and estimates, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. Potential risks include, but are not limited to, demand for our products, operating results of our subsidiaries, market conditions, and other factors discussed in our most recent annual report on Form 10-K and other documents filed with the Securities and Exchange Commission.

Although the company believes that the assumptions underlying these statements are reasonable, any of them can be proven inaccurate, and there can be no assurances that the results will be realized. The company undertakes no obligation to update the forward-looking statements made during today's call. In addition, references may be made to certain non-generally accepted accounting principles or non-GAAP measures for which you should refer to the appropriate disclaimers and reconciliation in the company's SEC filings and press releases. Kopin Corporation's Chief Executive Officer, Michael Murray, will begin today's call with an overview of Kopin's progress within the company's strategy. Following Michael, Kopin CFO, Richard Sneider, will review the company's Third Quarter 2024 results. I would now like to turn the conference over to Michael Murray. Michael?

Michael Murray (CEO)

Thank you, Brian. Good morning to everyone, and welcome to our Third Quarter 2024 earnings call. We'd like to take a moment to express our gratitude to all the veterans, both within and outside of our organization, as well as those currently serving in the armed forces. Their dedication and service are invaluable to Kopin's ongoing mission to save lives and enhance human performance through advancements in optical solutions. We are proud of the substantial progress we've made on our transformation plan, which is gaining momentum and achieving key milestones. We now project over $75 million in orders for 2024 and beyond, potentially the highest annual order total in our company's 40 year history. This order book includes repeat orders from existing customers, as well as significant new orders from both U.S. and international clients, demonstrating our growth in revenue, customer base, and market reach.

In the third quarter, we achieved $13.3 million in revenue, a 26% increase over Q3 2023, with continued sequential revenue growth. Defense products delivered $10.4 million in revenue, a 109% year-over-year increase. Notably, five new customers placed development orders, which we expect will drive multi-million dollar production orders in the years ahead, given these are multi-year indefinite delivery, indefinite quantity or IDIQ contracts secured by our customers. In defense, our order book has shown significant strategic progress. We reached the final production qualification milestone for our high-performance organic light-emitting diode on silicon display, designed for Collins Aerospace F-35 Lightning II Helmet-Mounted Display System, or HMDS. As the sole source supplier of high-brightness AMLCD displays for this system, we are fulfilling a multi-year agreement that should continue on for several more years.

Recently, we received a $2 million follow-on production order for these AMLCD displays, extending our backlog and preparing us for next-generation OLED on silicon micro-display production. We anticipate both display types will be in production for an extended period of time. We also secured a $1.3 million follow-on order for our Emerald micro-display module for a major weapon sight product as part of a multi-year production program. This positions us for strong revenue growth, especially as our larger thermal weapon sight program and subsequent production is expected to increase into fiscal year 2025. In the industrial market, we secured a $1.5 million follow-on contract for our Near-Eye thermal imaging system integrated into firefighters' masks. This system, featuring a miniaturized AMLCD and optics within the facepiece, enhances safety and effectiveness for firefighters.

Turning to our 3D AOI, automated optical inspection segment, we launched our next-generation SXGA FLCOS micro-display system called the R15. MIRTEC, a leading provider of 3D AOI technology in South Korea, secured our first purchase order for this device. This affordable, compact solution positions us well to meet growing demand in Asia and globally. Additionally, we received a production order for our high-resolution 4-megapixel 2K SLM system, also for 3D AOI integration. With the global 3D AOI market projected to grow from $700 million to $3 billion by 2030, Kopin is positioned to serve various segments: budget-sensitive with the R15, mid-range with our SXGA model, and high-resolution with the 2K-R11 model as well. In the medical market, our growth continues with another production order for the CR3 wearable surgical monitor from HMDmd.

Supported by positive feedback from surgical equipment manufacturers, we expect adoption to increase as more surgeons try the CR3 through HMDmd's Tier I partnerships. Overall, our book-to-bill ratio has exceeded expectations, and we are negotiating additional substantial orders anticipated by year-end. This progress reaffirms our strategy to focus Kopin on defense and high-performance integrated products. Notably, our new internal processes aimed at enhancing return on investment for internally funded research and development are showing promise and early results. Internal R&D investments have led to initial purchase orders and strong demand signals for our new products, which are robust, offer broader functionality, and command higher average selling prices due to the value they provide. Quality improvements also continue. Incoming inspection rates at our top customers reached 94% in Q3 and October as well, up from 86% in the previous quarter, positively impacting product gross margins and customer satisfaction.

We're making significant strides in quality and organizational evolution, with more progress to come. As our quality standards continue to improve, becoming more stable and predictable, we also need to innovate our systems, design processes, and manufacturing workflows to meet the rising demand and higher volume production expectations. A new strategic focus for 2025 will be enhancing manufacturing and systems automation. Now, turning to other key initiatives, including our One Kopin Initiative, in response to increased defense spending in Southeast Asia, Europe, and NATO countries, we have expanded the scope of our European-based 3D AOI sales team. They now promote the full range of Kopin products and capabilities to defense customers in Europe and Southeast Asia as well. Early indicators show this strategy is succeeding, as we're seeing new opportunities and foreign customers entering our pipeline. One of our foundational strategic initiatives, the FabLite strategy, remains on track.

Kopin continues to partner with multiple fabrication facilities across Asia, Europe, and the United States, specifically for U.S. DOD applications and our four display types. Our decision to strengthen OLED on silicon and our micro-LED capabilities for U.S. Department of Defense applications has been proven timely, given the possibility of further supply chain security requirements and potential tariffs under the new administration. Additionally, we're collaborating closely with government and industry partners to build a long-term, higher-volume, and more innovative manufacturing approach within the United States. Now, I'd like to highlight a few additional notable accomplishments from the quarter. This quarter, we expanded our medical technology portfolio by introducing proprietary high-resolution fast spatial light modulators, or SLMs, for use in fluorescence super-resolution microscope systems for biomedical research. These advanced SLMs enhance image resolution, often down to the molecular level, significantly advancing research capabilities at leading biomedical institutions worldwide.

In the defense sector, we partnered with Wilcox Industries on the FUSION CLAW, a cutting-edge head-borne information system offering integrated day-and-night heads-up display solutions. This partnership is the cornerstone of our IVAS strategy, which introduces an integrated visual augmentation system for warfighters supporting day-and-night capabilities compatible with current night vision goggles and helmet-mounted systems. With millions of night vision goggles in use today, this solution provides immediate market potential by enhancing telemetry and thermal imaging in a heads-up configuration, improving situational awareness. Additionally, at AUSA, we were featured in the QinetiQ Suite to showcase our NeuralDisplay Technology platform. NeuralDisplay is a sophisticated OLED or micro-LED hardware and software system that includes embedded sensors for eye tracking, position, and gaze detection, with the ability to process this tracking data in real-time through Kopin's proprietary AI-powered software within the display's backplane.

This real-time data just optimizes user experience in high-stakes environments. The platform has now reached alpha testing, marking a major milestone in the development of our Neural Display architecture. We believe this display system will be an ideal fit for the next generation of defense visual augmentation systems. It also has attracted significant interest from consumer spatial computing manufacturers, thanks to its ability to reduce size, weight, and power consumption while maintaining high image quality, eye and pupil tracking, and dynamic controls. We're extremely excited about this new technology. Currently, we are collaborating with several defense and consumer companies on innovative design approaches, software integration strategies, and exploring potential new business models. As we look to the future and see our business fundamentals strengthening, we're experiencing favorable market dynamics in the AR/VR sector that align with our mission and technology roadmaps.

Additionally, geopolitical factors and the new administration have created strong tailwinds for our business. Given these factors, we're increasingly optimistic about our financial trajectory for 2025 and beyond. With that, I'll now turn the call over to our CFO, Rich Sneider, to review our results from the third quarter in further detail. Over to you, Rich.

Richard Sneider (CFO)

Thank you, Michael. Turning to our financial results for the third quarter of 2024, total revenues from Q3 2024 were $13.3 million versus $10.6 million for the prior year, a 26% increase year-over-year. Product revenues for the third quarter ended September 28, 2024, were $10.9 million, compared to $5.5 million in the third quarter of September 30, 2023. The increase in product revenues was the result of higher defense product revenues, which increased $5.4 million year-over-year. In the third quarter of 2024, funded research and development revenues were $2.3 million, a decrease of $2.7 million as compared to Q3 of 2023 due to the completion of several programs, like the monochrome micro-LED program, which is now entering low-volume initial production.

Cost of product revenues for the third quarter of 2024 were $8.3 million, or 76% of net product revenues, compared with $5.4 million, or 99% of net product revenues in the third quarter of 2023. The decrease in cost of product revenues as a percent of sales was the result of a decrease in expected costs because of lower estimated rework costs, essentially improved quality. R&D expenses for the third quarter of 2024 were $2.6 million compared to $3.1 million in the year-ago quarter. This was primarily due to a decrease in funded R&D expense of approximately $1.2 million on U.S. defense programs that were previously noted were completed. This was partially offset by an increase of $700,000 in internal R&D expense for process improvements. SG&A expenses were $5.2 million in the third quarter of 2024, compared to $4.8 million in the third quarter of 2023.

The increase was primarily due to an increase in legal fees of $400,000, partially offset by a decrease in public relations fees of $100,000. Legal expenses associated with the BlueRadios matter in the third quarter of 2024 and 2023 were $1.5 million and $1.2 million, respectively. With the trial portion of the lawsuit behind us and potential appeals process in front of us, we expect legal fees to normalize at a much lower level than recently experienced. We believe the appeals process involves much less expense than funding a trial. Other expenses, net for Q3 of 2024 includes a $1.1 million impairment loss on equity investments. Turning to the bottom line, the net loss for the quarter of 2024 was $3.5 million, or $0.03 per share, compared with a net loss of $2.5 million, or $0.02 per share for the third quarter of 2023.

The amounts discussed above are based on our current estimates, and listeners should review our Form 10-Q for the nine months ended September 28, 2024, for any possible changes and, of course, additional information and filings. And with that, I'll turn it over to Michael for closing remarks.

Michael Murray (CEO)

Thanks, Rich. This quarter's results demonstrate our ongoing success in delivering solutions which improve the human experience, performance, and save lives. Our operational improvements, stronger customer relationships, and momentum in orders give us greater visibility and a clear plan towards achieving sustainable net income profitability. We continue to strengthen margins through improved quality rates, cost controls, and strategic investments in our products, automation, and our talented and dedicated workforce. Our pipeline of qualified opportunities has grown significantly in recent quarters, largely driven by the U.S. need to replenish stockpiles, modernization of defense technology and weaponry, and respond to recent geopolitical developments. Increased sovereign and NATO spending further boosts this trend. We anticipate that these new partnerships and progress will fuel full-rate production, and they'll lead to contributing larger future returns.

To capture these opportunities and accelerate our market momentum, we've recently expanded our North American business development team with two new hires, and we retained a consultant specializing in consumer applications. Thank you all for your time today, for your interest in Kopin. I'd also like to thank and extend our gratitude to our employees, our customers, and stakeholders for their dedication and continued support. With that, Operator, we'll now offer time to take some questions.

Operator (participant)

Thank you. At this time, if you would like to ask a question, please press the Star and one on your telephone keypad. You may remove yourself from the queue at any time by pressing Star two. Once again, that is Star and one if you would like to ask a question. We'll take our first question from Jaeson Schmidt with Lake Street. Your line is now open.

Jaeson Schmidt (Director of Research)

Yes, thanks for taking my questions, and congrats on the strong results. Michael, want to dig in a little bit on the international market? You noted some nice traction there. Just curious where you're seeing that. And I guess relatedly, is your sales infrastructure to address the international market fully built out at this point?

Michael Murray (CEO)

So international, I think, is a growth opportunity for us. Jason, thanks for the question. Right now, the international business is actually, I'd say, less than 5% of our total revenue this year. We do see that exceeding our expectations next year and the year after, just simply because of geopolitical issues in Israel, Ukraine, and some other hotspots that currently need the technology that we have. We also see the perturbation of NATO requesting and demanding 2% of GDP actually be spent. So I think, as we move forward, international business for us in defense specifically is going to grow exponentially. Moreover, we also see interesting trends in the medical side of the business with future potential medical customers globally here looking at the CR3 module, as well as those displays for high-end microscopes, as we talked about.

So overall, I think international is going to grow for us, and that's the pivot that we made with the 3D AOI team, which resides mostly in Europe. But we're not fully built out for international sales just yet. We expect to make some small investments and augmentations, if you will, to service that business next year and in the future.

Jaeson Schmidt (Director of Research)

Okay. That's helpful. And then I know you noted kind of a strong book-to-bill year today. Just curious what that number was for Q3?

Michael Murray (CEO)

Q3, it was slightly below one-to-one.

Jaeson Schmidt (Director of Research)

Gotcha. And then just the last one from me, and I'll jump back into queue. Obviously, it's early, but we'd just love to hear your thoughts on how your business might be potentially impacted with the change in administration.

Michael Murray (CEO)

Sure. So I think, firstly, I think the new administration, based on what we understand today, which is early, is going to be good for Kopin in the long run, mainly because of the strong emphasis on NATO to spend 2% of GDP, which was the previous administration's big focus. And I think that's going to continue, number one. Number two, I see the budget process including plus-up requirements for defense spending in the United States. So I think that's a second tailwind that we see. And then the third tailwind that we see with the new administration is just the ability for smaller companies, small-cap companies like Kopin, to grow. And I think that's a big focus of the new administration. So pound for pound, we see this as a positive for Kopin.

Jaeson Schmidt (Director of Research)

Perfect. Appreciate the caller. Thanks a lot, guys.

Michael Murray (CEO)

And one other note, Jason, real quick. Although our book-to-bill this quarter was not positive, the book-to-bill for the year remains ahead of schedule and positive. So I wanted to make that distinction.

Jaeson Schmidt (Director of Research)

Okay. Thank you.

Operator (participant)

Thank you. We'll take our next question from Victor Santiago with Stifel. Your line is now open.

Victor Santiago (Equity Research Associate)

Hey, good morning, guys. This is Victor on from Matt Sheerin. Just a question on revenue in the quarter. It was a bit better than we had expected of that kind of mid-single-digit sequential growth. Was that a function of pulling orders from Q4, or was that just your ability to ramp new programs in the quarter?

Richard Sneider (CFO)

It was a combination of product mix and our ability to produce. Remember, we're on 606, so essentially our revenues are not based on shipment. They're really based on percent completion. So to the extent the supply chain is flowing nicely, it allows us to get ahead and build product. And so the supply chain worked very well this quarter, and also we had a favorable product mix. Some of the smaller orders that you see actually have much bigger gross margins and are much more profitable.

Victor Santiago (Equity Research Associate)

Got it. And then I think last quarter you had talked about growing gross margin sequentially through the year. You guys saw a nice bump here in Q3. Can we expect that to continue going to Q4?

Richard Sneider (CFO)

That's the plan.

Victor Santiago (Equity Research Associate)

Got it. Fair enough. That's all I had. Thank you.

Operator (participant)

Thank you. And once again, that is Star and 1. If you would like to ask a question, we'll take our next question from Kevin Dede with H.C. Wainwright. Your line is now open.

Kevin Dede (Research Analyst)

Thanks, gentlemen, for having me on. Hi, Michael, Rich. Michael, would you mind diving into the Neural Display a little bit more? I mean, you spoke to specific interests both on DOD and the consumer side. You've got a new consumer applications consultant. I know it's early. I get it. But if you could give us a little more color there, we see that as an exciting opportunity for Kopin.

Michael Murray (CEO)

Sure. From a standpoint of Neural Display, we see the market basically repeating history. If you look at original cell phones, as an example, they were built with individual components, not much integration. And then over time, ICs won the day. Integrated circuits won the day. We see that same sort of trend with spatial computing devices or AR/VR goggles that sensor fusion systems or integrated circuits need to drive that innovation. And Neural Display is a great example of that. It removes six cameras from some of the spatial computing devices. Six cameras is very costly, very high power, and creates a lot of weight on the nose. So we think Neural Display has a tremendous value proposition in both consumer and medical, as well as obviously defense.

On the consumer side of things, we think all the consumer companies at this point in AR/VR are back to the drawing board, which is good news for us because we're farther down the path with neural display. I can't talk about some of the things we're working on because they are under NDA at this point, but we are making pretty substantial progress thus far.

Kevin Dede (Research Analyst)

Has the company decided on whether it might or might not offer a demo of it at CES? I know that had or was being considered at some point.

Michael Murray (CEO)

We're still trying. It's up for debate. We're struggling with it, quite frankly, to get a better image quality out of it. And we still have a pretty strong plan to make it to CES with the Neural Display as an actual display running our software and the AI. As you can imagine, in the last 18 months, that's been a Herculean lift for our engineering teams, so still TBD, that's the plan, but we are struggling with it.

Kevin Dede (Research Analyst)

Regarding, I think it was Victor's question on the change in the administration, I'm wondering if you've looked sort of the next layer of the onion and your supply chain and the potential for tariffs to impact that. How might you be hedging yourself?

Michael Murray (CEO)

Great question. Thankfully, one of the first strategic initiatives that we had, Kevin, was our FabLite model and the concern around our Chinese OLED deposition supply chain. I'm very pleased to report that we've moved our sensitive U.S. DOD applications to a new provider that is U.S. DOD approved. The vast majority of our components will have a dual source, U.S. DOD as well as our Chinese deposition partner, specific to OLED moving forward. We'll be complete that transition this quarter. So very pleased and proud of the team for their progress. And more importantly, we're actually seeing better quality results and better performance out of our new partner on our OLED displays. So tremendous progress in that area. And it was very timely that we took that decision when I came in a couple of years ago. So that strategy is now proving positive for us.

Kevin Dede (Research Analyst)

So I guess I'm wondering maybe if there's any way to quantify that. Do you have to worry about rotating manufacturing with a change in import policy?

Michael Murray (CEO)

No, not necessarily.

Kevin Dede (Research Analyst)

Okay.

Michael Murray (CEO)

No, it's more about we build our backplanes through either Taiwanese or Korean fabs, and then the deposition process can happen anywhere in the world where we see technology benefit or performance benefit or cost benefit, as an example. And that's part of the FabLite strategy is we will go to the partners that have the best cost, best quality, and best performance. So that allows us to do that, which is take our backplane designs and then deposit OLED or micro-LED material where it makes best sense for our customer base, the geopolitical issues. So it just makes us much more flexible. But as I mentioned in my prepared remarks, we also have an advocacy for a larger footprint here in the United States for Kopin. And that larger footprint is something that we're actively working on with the government, the government customers.

I'm very pleased to report that the government customer is supporting us in that endeavor, whether that be through DPA or CHIPS Act funding. We do have a larger advocacy around building out a footprint here in the United States for all of our technology needs for the U.S. DOD.

Kevin Dede (Research Analyst)

I'd imagine that's a pretty long lead time though, right?

Michael Murray (CEO)

Correct.

Kevin Dede (Research Analyst)

Yeah. Okay. On backlog, Michael, help me with some of the numbers. You mentioned, I think in your prepared remarks, a $75 million order number, which I think is up from $55 million when you last talked about the June quarter. I'm wondering if I'm in the right ballpark on those and what drove the big increase.

Michael Murray (CEO)

You're exactly right. From Q2, we were sitting with $55 million of purchase orders in the calendar year at that point. Our expectations due to several negotiations that are ongoing that we'll receive in the realm of $20 million of new orders for this quarter. We might see a little bit of creep over the Christmas holiday into Q1, but my sense is right now the negotiations should land us with those orders in Q4. And again, if we do end up with $75 million of purchase orders for this year, that would be a record for our 40-year-old company.

Kevin Dede (Research Analyst)

I appreciate that. Congratulations. Is there any more insight, or should we look to pretty much what you focused on, mostly DOD, foreign and domestic, and medical?

Michael Murray (CEO)

I think that's accurate. What we're expecting this quarter is some influx of thermal weapon sight orders for production next year, as well as our helmet-based programs for rotary wing and fixed wing applications. So we're expecting orders. That customer for the fixed wing, we already mentioned earlier in the call, we're expecting orders for carry-on production. The rotary wing customer is Elbit, and they are otherwise engaged, as you can imagine, Kevin, in Israel at the moment. So we've been expecting those orders for quite some time, and we are seeing light at the end of the tunnel to receive those orders for our rotary wing applications this quarter.

Kevin Dede (Research Analyst)

Okay. Last question for me before I hop back in. I understand that Judge Kane is going to consider the ruling in Massachusetts, and I was wondering, number one, whether or not you have any insight on how that might be going. And number two, Rich talked to, I think, $1.2 million and $1.5 million in litigation-related expense, I think, in the September quarter this year and last, but I got confused on which one was which. And what would you expect that litigation expense to fall to in the December quarter? So $1.5 [million] is 2024. $1.2 [million] is 2023. Okay. Got it.

Michael Murray (CEO)

And historically, we're somewhere now. At some point, there may be an appeal, and there will be a chunk of expense that we estimate will be $500,000-$600,000. When that's going to happen, we don't know. It's all dependent on when the judge ultimately puts out an opinion. Otherwise, we run about $150,000-$200,000 a quarter in legal expenses between patents and just normal public company stuff. And we do not have any visibility into when Judge Kane in Colorado will render his opinion.

Kevin Dede (Research Analyst)

Thank you for offering that, gentlemen. I appreciate you entertaining my questions. Congrats on the nice job in the quarter.

Michael Murray (CEO)

Thanks, Kevin. Take care.

Operator (participant)

We have no further questions in the queue at this time. I'll turn the program back over to Michael Murray.

Michael Murray (CEO)

Thank you, operator. I just wanted to say thank you to the tremendous team here at Kopin for their focus, dedication, and exemplary results this quarter. It's a great milestone in our path to further revenue and gross margin expansion. And we thank everyone for joining us today. Thank you very much.

Operator (participant)

This does conclude today's program. Thank you for your participation. You may disconnect at any time and have a wonderful day.